DNDi - NewsLetter


HOME
ABOUT DNDi EDITORIAL: "NECT is a Success but Many Challenges Still Remain" CALENDAR HOW YOU CAN HELP DNDi?
Nifurtimox-Eflornithine Combination Therapy: An Improved Treatment for Sleeping Sickness Gerardo Priotto : Portrait A Major Step Forward in Improving Treatment Options for HAT NECT: Next Steps Sleeping Sickness [Human African Trypanosomiasis-HAT] What DNDi Does to Address Sleeping Sickness HAT Projects Supported by Public and Private Funds TDR investigates NECT in Uganda The Key Role Played by the HAT Platform Challenges of Establishing and Monitoring a GCP Trial in Remote Settings Challenges to Follow HAT Patients Evolution After A Hope for Surviving Sleeping Sickness: Joseph’s Story Thank you Angèle Malaria: ASAQ Obtains WHO Prequalification Chagas Disease: Agreement between Lafepe and DNDi on Safe, Easy-to-Use Treatment for Children Visceral Leishmaniasis: 11th LEAP meeting takes place in Addis Ababa to Discuss VL Strategy Plan DNDi Event: Indian Scientists Catalyse Efforts in Research and Development for New Treatments for Neglected Diseases BBC Documentary on Sleeping Sickness Fexinidazole Progresses into Clinical Development Discovery Programmes for HAT Contacts DNDi Credits

Nifurtimox-Eflornithine Combination Therapy: An Improved Treatment for Sleeping Sickness The NECT Phase III pivotal study conclusively demonstrates that the coadministration of oral nifurtimox and intravenous eflornithine (NECT) is a safe, effective treatment for stage 2 HAT patients, and more practical than eflornithine monotherapy. Background: the need for combination therapies for stage 2 HAT The rationale for the NECT (nifurtimoxeflornithine combination therapy) study lies in the fact that, for stage 2 HAT, there were few available drugs, each with serious limitations (see on existing treatments) read more
Sleeping Sickness [Human African Trypanosomiasis - HAT] 60 million people at risk in sub-Saharan Africa What is the annual impact of HAT? 50,000-70,000 cases(1) 1,525,000 DALYs(2) (3) Large proportions of communities can be affected by HAT, with serious social and economic consequences.... read more TDR investigates NECT in Uganda As part of a larger collaborative effort with DNDi and Epicentre, the TDR has sponsored a clinical trial comparing the NECT combination with the standard eflornithine regimen for the treatment.... read more Challenges of Establishing and Monitoring a GCP Trial in Remote Settings Working in rural areas such as the NECT trial sites in Dipumba and Katanda in the Democratic Republic of the Congo (DRC), researchers face many challenges that do not exist in other settings. ... read more Thank you Angèle One key team member of the NECT study was Angèle Ngo-On, who provided logistical support from November 2005 through August 2008... read more Malaria: ASAQ Obtains WHO Prequalification Chagas Disease: Agreement between Lafepe and DNDi on Safe, Easy-to-Use Treatment for Children Visceral Leishmaniasis: 11th LEAP meeting takes place in Addis Ababa to Discuss VL Strategy Plan DNDi Event: Indian Scientists Catalyse Efforts in Research and Development for New Treatments for Neglected Diseases BBC Documentary on Sleeping Sickness		HAT Projects Supported by Public and Private Funds Thanks to continuous support from our public and private donors, from 2003 to 2008 DNDi has disbursed EUR 16.5 million for its portfolio of human African trypanosomiasis (HAT) projects. read more The Key Role Played by the HAT Platform Built around the national HAT control programmes of the most affected countries, the HAT Platform is a regional network to strengthen research capacity on human African trypanosomiasis (HAT)... read more A Hope for Surviving Sleeping Sickness: Joseph’s Story Sleeping sickness (HAT) has accompanied the Mutombo family for the past two years. Alongside his mother, Joseph is resting tiredly at a specialised treatment centre after they underwent painful lumbar punctures... read more Fexinidazole Progresses into Clinical Development In early 2009, DNDi plans to advance fexinidazole into first-in-human, Phase I studies. Fexinidazole is the first compound to be taken by DNDi... read more

Published by Drugs for Neglected Diseases Initiative - 15 Chemin Louis-Dunant 1202 Geneva Switzerland - Photo credits: DNDi unless otherwise stated - Editor: Sadia Kaenzig - Tel: +41 22 906 9230 - Fax: +41 22 906 9231 - www.DNDi.org